You have successfully logged out.
Not registered yet?
Annual Report 2022
2022 was characterized by disruption. The most dramatic impact being Russia‘s war against Ukraine. In addition, we experienced an energy crisis, inflation, and unreliable supply chains. This has, and will continue to pose major challenges to all of us. At B. Braun, we responded early and began consistently adapting our business models to this changing world, allowing us to drive strategic projects forward and continue our investments.
This information is meant for medical professionals only. Please confirm that you are a medical professional before accessing the information.
Confirm Yes, I am a health care professional. Cancel No, I am not a health care professional.As a health care company, we are aware of our special responsibility—particularly now, when the challenges facing health care systems continue to mount. We are working hard to ensure supply availability to provide quality health care to more people around the world.
B. Braun continued its growth path. In view of the volatile market environment, we are satisfied with a currency-adjusted increase in sales of 3.6 percent. Although we did not reach our strategic target corridor of 5 to 7 percent, we were able to continue our growth despite significant negative factors. In the Group currency, sales increased by 8.1 percent to € 8.5 billion (previous year: € 7.9 billion).
Our profit was burdened considerably by cost increases, especially for raw material, energy, and logistic costs, as well as one-time effects. Although we could not completely compensate for this impact, with global steps such as price increases and cost reductions, we successfully stabilized our profit.
| 2021 | 2022 | Change in % | |
| Sales (in € million) | 7,859.8 | 8,499.8 | + 8.1 |
| EBITDA (in € million) | 1,101.9 | 997.2 | - 9.5 |
| Profit before taxes (adjusted; in € million) | 408.6 | 275.0 | - 32.7 |
| Consolidated net income (adjusted; in € million) | 300.1 | 211.7 | - 29.5 |
| Employees (as of December 31) | 66,234 | 65,055 | - 2.6 |
We did not slow down the implementation of milestones in our strategy, B. Braun—the next decade. This includes further investment in the medical technology of tomorrow. We expanded our capacity in our core business, for example by expanding and optimizing our sites in Germany, Italy, Spain, Switzerland, USA and Vietnam. We also acquired the remaining shares in Schölly Fiberoptic GmbH, a specialist in endoscopic visualization. We spent € 466.1 million on research and development (adjusted; previous year: € 416.9 million).
We also employ technological developments to weave sustainability through our supply chains, production and logistics processes, and resource management. We have continued to improve our sustainability structures to attain a competitive edge through professional sustainability management for the future. We make our business decisions with current and future generations in mind and take responsibility for the protection and improvement of people's health around the world.
Together, we at B. Braun have successfully strengthened our resilience during a difficult 2022. We deepened our commitment to our customers and invested in our future. We will continue to change and move ahead—with the goal of using our own resources to grow and drive advancements in health care.
With your personalized account, your online experience will be easier, more comfortable and safe.